Search company, investor...


Founded Year



Series A | Alive

Total Raised


Last Raised

$11.84M | 3 mos ago

About Enzyre

Enzyre develops a diagnostic device to provide patients with the flexibility to assess their coagulation status regardless of where they are. The device requires a small volume of blood to measure up to sixteen reactions simultaneously with high sensitivity and specificity without any laboratory infrastructure. The company was founded in 2016 and is based in Nijmegen, Netherlands.

Headquarters Location

Transistorweg 5

Nijmegen, 6534-AT,


+31 024 6690036

Enzyre's Product Videos

Compete with Enzyre?

Ensure that your company and products are accurately represented on our platform.

Enzyre's Products & Differentiators


    The EnzySystem prevents patients from bleeding to death.

Expert Collections containing Enzyre

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Enzyre is included in 3 Expert Collections, including Medical Devices.


Medical Devices

8,605 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,593 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Health IT

7,901 items

Enzyre Patents

Enzyre has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics



Coagulation system, Coagulopathies, Anticoagulants, Blood tests, Hematology


Application Date


Grant Date


Related Topics

Coagulation system, Coagulopathies, Anticoagulants, Blood tests, Hematology



Latest Enzyre News

Enzyre Closes €12 Million Series A Funding Round

Jan 13, 2023

Company will use the money to advance a hemophilia diagnostic technology platform. Michael Barbella, Managing Editor01.13.23 Enzyre  has bolstered its finances with a €12 million Series A financing led by Oost NL, with participation from i&i Biotech Fund, Demcon Investment (as technology partner) and existing investors Takeda Ventures and Novalis Biotech. Part of the funding is an Innovation Credit from the Dutch government. “We are delighted to have closed this successful financing round which validates our technology and will underpin our ongoing development as we take Enzyre forward into the next phase of growth," Enzyre CEO Guido Maertens said. "We value Takeda’s continued support and welcome the commitment from a strong cohort of new and existing investors. Together we look forward to improving the quality of life for patients living with bleeding disorders by driving forward our goal to transform their standard of care.”   Proceeds from the financing will allow Enzyre to further develop its diagnostic technology platform, EnzyPad, which will help hemophilia patients determine and monitor their coagulation status from home in real-time. The funds will support clinical trial registrations, the establishment of a sustainable manufacturing line, and investment in expanding applications in the critical care setting. Enzyre’s first product, Hemophilia EnzyCard, uses the company’s proprietary EnzyPad platform technology to determine the coagulation status of patients with hemophilia, a rare genetic disorder estimated to affect more than 800,000 people worldwide.1 Those with hemophilia A lack sufficient blood- clotting factor VIII (FVIII) activity, causing them to bleed for longer after an injury compared to healthy subjects. Due to the complexities associated with managing the condition, patients benefit from being able to safely monitor their condition at home while potentially staying connected with their care team by telemedicine. Enzyre’s technology will enable patients to self-test in a home setting, and eventually transfer their coagulation status to their treating physician through a mobile phone app and a cloud- based application. This will allow for timely personalized therapy adjustments that may improve clinical outcomes while avoiding unnecessary travel and hospital exposure, ultimately decreasing overall treatment burden and cost for patients and healthcare systems. “We are excited to be working with Enzyre in developing a truly innovative technology that is a potential game-changer in the management of Hemophilia A and other bleeding disorders. Patient outcomes and quality of life will be dramatically improved by the ability of physicians to monitor coagulation status in real-time and we see great potential for the product to enhance personalized care,: said Pieter Rhemrev, senior investment manager at Oost NL, acting as lead investor of the syndicate. "We look forward to joining this team and our syndicate partners in supporting Enzyre’s pathway to future success.”   Enzyre is a spin-out from Radboud University Medical Center in The Netherlands, founded by Maertens and Waander van Heerde. The company is developing a diagnostic device to provide patients with the flexibility to assess their coagulation status regardless of where they are. Enzyre’s platform requires a small volume of blood to measure up to 16 reactions simultaneously with high sensitivity and specificity without any laboratory infrastructure, at home, on the road or in a critical care setting. Oost NL is the development company of the Eastern Netherlands. It is strengthening the regional economy on behalf of the Ministry of Economic Affairs and Climate Policy and the provinces of Overijssel and Gelderland, by investing public money in entrepreneurs in the east of the Netherlands. Reference

Enzyre Frequently Asked Questions (FAQ)

  • When was Enzyre founded?

    Enzyre was founded in 2016.

  • Where is Enzyre's headquarters?

    Enzyre's headquarters is located at Transistorweg 5, Nijmegen.

  • What is Enzyre's latest funding round?

    Enzyre's latest funding round is Series A.

  • How much did Enzyre raise?

    Enzyre raised a total of $13.48M.

  • Who are the investors of Enzyre?

    Investors of Enzyre include Novalis Biotech, Government of the Netherlands, Takeda Ventures, Demcon, Oost NV and 5 more.

  • Who are Enzyre's competitors?

    Competitors of Enzyre include XaTek Inc. and 1 more.

  • What products does Enzyre offer?

    Enzyre's products include EnzySystem.

  • Who are Enzyre's customers?

    Customers of Enzyre include Takeda Pharmaceutical Company Limited .

Compare Enzyre to Competitors

XaTek Inc.

Developer of blood coagulation testing chip. The company develops a chip that tests the coagulation ability of blood. The chip is portable, WiFi enabled, and requires only a single drop of blood for it's analysis.


rHEALTH is a biotechnology company that provides health solutions that focus on specific conditions with advanced rHEALTH diagnostics and autonomous health platforms. It was founded in 2010 and is based in Bedford, Massachusetts.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.